Complement System Proteins (Complement)

Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).

Also Known As:

Networked: 21537 relevant articles (577 outcomes, 2077 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lambris, John D: 88 articles (12/2015 - 08/2002)
2.	Holers, V Michael: 62 articles (11/2015 - 04/2002)
3.	Morgan, B Paul: 58 articles (12/2015 - 01/2002)
4.	Tomlinson, Stephen: 58 articles (03/2015 - 02/2002)
5.	Blom, Anna M: 51 articles (01/2016 - 03/2003)
6.	Zipfel, Peter F: 51 articles (10/2015 - 06/2002)
7.	Meri, Seppo: 39 articles (01/2015 - 06/2002)
8.	Ward, Peter A: 37 articles (01/2016 - 07/2002)
9.	Skerka, Christine: 37 articles (10/2015 - 06/2002)
10.	Stahl, Gregory L: 37 articles (06/2015 - 07/2002)

Related Diseases

1.	Infection 02/01/2002 - "Complement (C) is one of the most critical defence mechanisms of the innate immunity against cerebral infection by viruses, bacteria and fungi, with different molecular pathways contributing to the clearance of the invading pathogens. " 06/01/1980 - "The complement fixation test was shown to be most effective in the detection of recent infections." 01/15/2010 - "The host complement system plays an important role in protection against infections. " 04/01/2007 - "As an important component of innate immunity, complement has been shown to be necessary for protection against numerous microbial infections. " 11/09/2006 - "Resistance to infection and clearance of cell debris in mammals depend on the activation of the complement system, which is an important component of innate and adaptive immunity. "
2.	Neoplasms (Cancer) 01/01/2000 - "In vivo tumor models play an important role in the evaluation of the therapeutic efficacy of these strategies, and complement in vitro approaches (see Chapter 7) designed to evaluate and compare different P450 genes and different P450 gene/prodrug combinations. " 01/01/1989 - "Depletion of immune-sponge-derived cells with anti-Thy1.2, anti-Lyt2.2 or anti-L3T4 and complement resulted in a marked decrease in tumor-inhibitory activity. " 12/01/2011 - "Low tumor load can be eliminated by complement alone, whereas elimination of high tumor load requires multiple effector mechanisms." 09/01/1994 - "Haemodilution causes a significant reduction in the capacity of the complement system during operation, whereas inhibitory factors associated with the cancer or operation and anaesthesia could not be demonstrated. " 01/01/1989 - "Successful therapy in C5-complement-deficient tumor-bearing mice suggests that complement-dependent cytotoxicity does not play a major role. "
3.	Inflammation 08/01/2003 - "Phagocytosis of complement-opsonized targets is a primary function of neutrophils at sites of inflammation, and the clearance of neutrophils that have phagocytosed microbes is important for the resolution of inflammation. " 12/01/1997 - "Genetic complement deficiencies or complement depletion have been proven to be beneficial in reducing tissue injury in a number of animal models of severe complement-dependent inflammation. " 04/01/2000 - "In the last years a variety of studies demonstrated beneficial, organ protective effects of complement modulation in models of severe inflammation. " 01/01/2014 - "Combined inhibition of CD14 and complement, two main inducers of the inflammatory response, have proved particularly effective in attenuating Gram-negative bacteria-induced inflammation. " 05/01/1979 - "At present, we have no drugs that are effective in humans in controlling the activation of complement and complement-mediated inflammation. "
4.	Proteinuria 01/01/2007 - "Resulted in a significant improvement; serum albumine (3 +/- 0,8 vs 3,9 +/- 0,5 g/dL) p<0.01, and decreased of proteinuria (4,2 +/- 2,6 vs 1,8 +/- 2,2 g/ 24 hours) p<0.05, complement fractions improvement significantly, C3 and CH50 p<0.05, C4 p<0.01. " 12/01/1989 - "Complement depletion of neutrophil-depleted rabbits resulted in a further significant reduction in proteinuria 50.1 +/- 12.2 mg/24 h, P less than 0.05; versus neutrophil-depleted, complement-intact rabbits), indicating that both neutrophil accumulation and complement activation independent of neutrophils contribute to injury in this model. " 10/01/2014 - "This intervention proved effective and resulted in complement inhibition, sustained remission of proteinuria and preservation of renal function. " 02/01/1997 - "This study investigated the contribution of local complement synthesis by studying gene expression of the classical pathway component C4 in relation to the site of the tissue injury and the development of proteinuria induced by the pathogenic antibody (sheep anti-GP330). " 12/01/1985 - "This study compares the ability of antibody to induce injury in normal, PMN-depleted and dual (i.e., PMN + complement)-depleted rabbits by assessing the quantity of kidney-fixed antibody (KFA) necessary to induce proteinuria. "
5.	Hemolysis 01/01/2014 - "Indeed, in the last decad the anti-C5 monoclonal antibody has proven effective for the treatment of PNH, resulting in a sustained control of complement-mediated intravascular hemolysis, with a remarkable clinical benefit. " 11/01/2012 - "In the last decade the anti-C5 monoclonal antibody has been proven effective for the treatment of PNH, resulting in a sustained control of complement-mediated intravascular hemolysis, with a remarkable clinical benefit. " 03/01/2002 - "Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis." 03/01/2015 - "This study investigated whether Stx2 induces hemolysis and whether complement is involved in the hemolytic process. " 11/01/2014 - "The objective of this study was to develop a simple rat model of complement-mediated acute intravascular hemolysis. "

Related Drugs and Biologics

1.	Antibodies
2.	Immunoglobulin G (IgG)
3.	Antigen-Antibody Complex (Immune Complex)
4.	Antigens
5.	eculizumab
6.	cobra venom factor
7.	Proteins (Proteins, Gene)
8.	Immunoglobulin M (IgM)
9.	Monoclonal Antibodies
10.	Immunoglobulins (Immunoglobulin)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
4.	Transplants (Transplant)
5.	Heterologous Transplantation (Xenotransplantation)